Neurological Illness Following Treatment with Fludarabine

Overview

Journal Br J Cancer

Specialty Oncology

Date 1994 Nov 1

PMID 7947105

Citations 4

Authors

P W Johnson

J Fearnley

P Domizio

J Goldin

K Nagendran

J Gawler

A Z Rohatiner

T A Lister

Affiliations

Soon will be listed here.

Abstract

Fludarabine is a comparatively new drug for the treatment of low-grade lymphoid malignancy. This report describes five cases of unusual neurological illnesses occurring after treatment with fludarabine. These suggest that caution should be exercised in patients receiving fludarabine who develop neurological abnormalities, with prompt investigation and if necessary cessation of the drug.

Citing Articles

Diabetes insipidus and Guillain-Barré-like syndrome following CAR-T cell therapy: a case report.

Koch C, Fleischer J, Popov T, Frontzek K, Schreiner B, Roth P J Immunother Cancer. 2023; 11(1).

PMID: 36690387 PMC: 9872508. DOI: 10.1136/jitc-2022-006059.

A Review of Acute and Long-Term Neurological Complications Following Haematopoietic Stem Cell Transplant for Paediatric Acute Lymphoblastic Leukaemia.

Gabriel M, Hoeben B, Uhlving H, Zajac-Spychala O, Lawitschka A, Bresters D Front Pediatr. 2022; 9:774853.

PMID: 35004543 PMC: 8734594. DOI: 10.3389/fped.2021.774853.

Oral fludarabine.

Plosker G, Figgitt D Drugs. 2003; 63(21):2317-23.

PMID: 14524733 DOI: 10.2165/00003495-200363210-00004.

Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Adkins J, Peters D, Markham A Drugs. 1997; 53(6):1005-37.

PMID: 9179529 DOI: 10.2165/00003495-199753060-00007.

References

Suzuki J, Takaku A . Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol. 1969; 20(3):288-99. DOI: 10.1001/archneur.1969.00480090076012. View

Warrell Jr R, Berman E . Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986; 4(1):74-9. DOI: 10.1200/JCO.1986.4.1.74. View

Spriggs D, Stopa E, Mayer R, SCHOENE W, Kufe D . Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986; 46(11):5953-8. View

Chun H, Caryk S, Hoth D . Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986; 70(10):1225-8. View

Merkel D, Griffin N, Von Hoff D . Central nervous system toxicity with fludarabine. Cancer Treat Rep. 1986; 70(12):1449-50. View

Von Hoff D . Phase I clinical trials with fludarabine phosphate. Semin Oncol. 1990; 17(5 Suppl 8):33-8. View

Keating M, OBrien S, Kantarjian H, Plunkett W, Estey E, Koller C . Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993; 81(11):2878-84. View

Whelan J, Davis C, Rule S, Ranson M, Smith O, Mehta A . Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991; 64(1):120-3. PMC: 1977289. DOI: 10.1038/bjc.1991.253. View

Puccio C, Mittelman A, Lichtman S, Silver R, Budman D, Ahmed T . A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol. 1991; 9(9):1562-9. DOI: 10.1200/JCO.1991.9.9.1562. View

10.

Hochster H, Kim K, Green M, Mann R, NEIMAN R, Oken M . Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. J Clin Oncol. 1992; 10(1):28-32. DOI: 10.1200/JCO.1992.10.1.28. View

11.

Cohen R, Abdallah J, Gray J, Foss F . Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med. 1993; 118(2):114-6. DOI: 10.7326/0003-4819-118-2-199301150-00007. View

12.

Kornblau S, Estey E . Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia. Leukemia. 1993; 7(3):378-83. View

13.

Keating M, Kantarjian H, OBrien S, Koller C, Talpaz M, Schachner J . Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991; 9(1):44-9. DOI: 10.1200/JCO.1991.9.1.44. View